<DOC>
	<DOCNO>NCT01236898</DOCNO>
	<brief_summary>The aim study investigate pharmacokinetics safety N-acetylneuraminic acid patient Distal myopathy rim vacuole ( DMRV ) - hereditary inclusion body myopathy ( hIBM ) . Dosages 800mg single three time day 800mg 3 time day 5 consecutive day . N-acetylneuraminic acid N-glycolylneuraminic acid serum urine measure oral administration N-acetylneuraminic acid .</brief_summary>
	<brief_title>Pharmacokinetic Study N-acetylneuraminic Acid</brief_title>
	<detailed_description />
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>Confirmed mutation GNE gene No severe complication inform consent obtain More 40 kg weight administration Hepatic laboratory parameter ( AST , ALT , γ‐GTP ) Renal laboratory parameter ( Cr , BUN ) great three time upper limit reference value Presence history clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , metabolic , gastrointestinal , brain , psychiatric , neurologic disease Intake supplement contain sialic acid , St. John 's wort grapefruit within 7 day Enrollment another investigational study within 3 month More 400 mL blood donation within 3 month Presence alcohol drug dependency Women pregnant , breast feed possible pregnant . Patients investigator judge appropriate subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>N-acetylneuraminic acid ,</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hIBM</keyword>
</DOC>